N.J., Oct. 20, 2016 - Pacira Pharmaceuticals, Inc. (PCRX) today
announced the appointment of two key individuals who will assume
leadership roles within the companys commercial organization.
Thomas Sluby has been named Vice President, Sales and Matthew
Lehmann has been appointed Vice President, Marketing
Emerging Therapies; both individuals will report to Robert Weiland,
Chief Commercial Officer.
Sluby is responsible for the coordination, management, and leadership
of the Pacira sales organization, overseeing all aspects of
sales execution and customer relations. Mr. Sluby will work
closely with the commercial team on the development and implementation
of sales and product strategies for EXPAREL® (bupivacaine
liposome injectable suspension).
Lehmann will be responsible for the development, implementation,
and execution of market strategies and tactics, initially focusing
on the EXPAREL nerve block launch subsequent to approval. Pacira
is currently enrolling two Phase 3 studies in lower and upper
extremity nerve blocks. Mr. Lehmann will also oversee development
of the marketing and sales approaches for future EXPAREL indications
and the launch of additional products in the Pacira pipeline.
are excited to add Tom and Matt, two seasoned pharmaceutical
executives with long track records of success building and executing
on comprehensive commercialization strategies, to the Pacira
leadership team, said James Scibetta, President of Pacira.
We expect these key additions to the commercial side of
our business to significantly contribute to the success of EXPAREL
infiltration in the acute care marketplace, while positioning
the company for future success, beginning with the planned launch
of EXPAREL for nerve block.
Sluby joins Pacira from inVentiv Health, where he served as
National Business Director, responsible for overseeing the sales
and performance management of three national sales forces. Prior
to this position, Mr. Sluby served as Senior Vice President
of Global Client Relations for Taconic BioSciences, where he
led a global sales and marketing team. Mr. Sluby also held several
management roles during a 15-year period at Eisai, Inc., including
National Sales Director of Neurology, Gastroenterology and LTC/Hospital,
where he drove revenue in therapeutic areas ranging from Alzheimers
and acid reflux to epilepsy and low-molecular-weight heparin.
to Pacira, Mr. Lehmann held various executive positions during
a 21-year career at AstraZeneca, most recently as Head of the
Neuroscience Franchise where he was responsible for the successful
market build-out and launch of Movantik®. Mr. Lehmann also
served as Executive Director, Commercial Leader for Seroquel
XR® and Movantik, overseeing all commercial decisions covering
healthcare professional, consumer, and managed markets marketing,
as well as government affairs and pricing work.